<DOC>
	<DOCNO>NCT02184247</DOCNO>
	<brief_summary>Study compare bioavailability 350 mg Bronchoretard® - sustained-release theophylline ( anhydrous ) product respect reference product , Theo Dur® 300 mg theophylline anhydrous ( sustained-release product ) compare rate extent absorption theophylline base single multiple-dose profile .</brief_summary>
	<brief_title>Bioavailability Two Sustained-release Theophylline Products Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Theophylline</mesh_term>
	<criteria>Healthy , nonsmoking male subject 18 45 year age Body weight within 10 % ideal weight accord Body Mass Index ( BMI ) Normal health base medical history finding within range clinical acceptability , respect physical examination ( include electrocardiogram vital sign ) special investigation Ability comprehend willingness sign statement inform consent ( screen studyspecific procedure ) History serious systemic organ disease A major illness 3 month commencement studyrelated procedure Significant physical organ abnormality History hypersensitivity theophylline xanthine derivative Use medication within 2 week first administration study medication Participation another study experimental drug within 8 week first administration study medication Treatment within previous 3 month drug welldefined potential adversely affect major organ system ( example chloramphenicol , may cause bone marrow suppression ) Donation blood 8 week first administration study medication History , current compulsive alcohol abuse ( &gt; 10 drink per week ) , regular exposure substance abuse Positive test HIV hepatitis B antigens within previous 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>